Nicotine immunonanotherapeutics
First Claim
Patent Images
1. A composition comprising:
- (1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises an immunofeature surface comprising a plurality of nicotine moieties,wherein the immunofeature surface binds to antigen presenting cells with high avidity and low affinity as compared to an antibody that is specific for an antigen presenting cell-expressed surface antigen; and
(2) a pharmaceutically acceptable excipient.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.
-
Citations
31 Claims
-
1. A composition comprising:
-
(1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises an immunofeature surface comprising a plurality of nicotine moieties, wherein the immunofeature surface binds to antigen presenting cells with high avidity and low affinity as compared to an antibody that is specific for an antigen presenting cell-expressed surface antigen; and (2) a pharmaceutically acceptable excipient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 30, 31)
-
-
23. A composition comprising:
-
(1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises a plurality of nicotine moieties in an amount effective to provide a humoral response to the nicotine moieties; and (2) a pharmaceutically acceptable excipient. - View Dependent Claims (24, 25, 26, 27, 28, 29)
-
Specification